Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029289 | 0.86 | SIGMAR1 (0.38) | CCR2CYP2D6KCNH2CPB1SIGMAR1 | |
| SCHEMBL5030356 | 0.81 | CCR2 (0.43) | CCR2CYP2D6KCNH2CCR5 | |
| SCHEMBL5033692 | 0.80 | CCR2 (0.61) | CCR2CYP2D6KCNH2CPB1CCR5 | |
| SCHEMBL5033696 | 0.80 | CCR2 (0.61) | CCR2CYP2D6KCNH2CPB1CCR5 | |
| SCHEMBL5029168 | 0.72 | CPB1 (0.36) | CPB1SIGMAR1 | |
| SCHEMBL5027345 | 0.71 | CCR2 (0.53) | CCR2CYP2D6KCNH2CCR5 | |
| SCHEMBL5027332 | 0.71 | CCR2 (0.53) | CCR2CYP2D6KCNH2CCR5 | |
| SCHEMBL5027340 | 0.71 | CCR2 (0.53) | CCR2CYP2D6KCNH2CCR5 | |
| SCHEMBL5027115 | 0.70 | CCR2 (0.43) | CCR2CYP2D6KCNH2CCR5REN | |
| SCHEMBL5027117 | 0.70 | CCR2 (0.43) | CCR2CYP2D6KCNH2CCR5REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CCR2 3/4885CYP2D6 3033/4885KCNH2 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.